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Abstract
S100B, established as prevalent protein of the central nervous system, is a peripheral biomarker for blood-brain barrier
disruption and often also a marker of brain injury. However, reports of extracranial sources of S100B, especially from adipose
tissue, may confound its interpretation in the clinical setting. The objective of this study was to characterize the tissue
specificity of S100B and assess how extracranial sources of S100B affect serum levels. The extracranial sources of S100B were
determined by analyzing nine different types of human tissues by ELISA and Western blot. In addition, brain and adipose
tissue were further analyzed by mass spectrometry. A study of 200 subjects was undertaken to determine the relationship
between body mass index (BMI) and S100B serum levels. We also measured the levels of S100B homo- and heterodimers in
serum quantitatively after blood-brain barrier disruption. Analysis of human tissues by ELISA and Western blot revealed
variable levels of S100B expression. By ELISA, brain tissue expressed the highest S100B levels. Similarly, Western blot
measurements revealed that brain tissue expressed high levels of S100B but comparable levels were found in skeletal
muscle. Mass spectrometry of brain and adipose tissue confirmed the presence of S100B but also revealed the presence of
S100A1. The analysis of 200 subjects revealed no statistically significant relationship between BMI and S100B levels. The
main species of S100B released from the brain was the B-B homodimer. Our results show that extracranial sources of S100B
do not affect serum levels. Thus, the diagnostic value of S100B and its negative predictive value in neurological diseases in
intact subjects (without traumatic brain or bodily injury from accident or surgery) are not compromised in the clinical
setting.
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Introduction
S100B, a protein produced primarily by brain astrocytes, is an
established peripheral biomarker of blood-brain-barrier perme-
ability associated with various CNS (central nervous system)
injuries [1,2]. Elevated levels accurately reflect the presence of
neuropathological conditions including traumatic head injuries
[3–5], psychiatric disorders [6], cerebrovascular insults [7] and
neurodegenerative diseases [8], while normal levels reliably
exclude major CNS pathology [4,9,10]. Its potential clinical use
in the therapeutic decision making process is substantiated by a
vast body of literature validating variations in serum 100B levels
with standard modalities for prognosticating the extent of CNS
damage: alterations in neuroimaging, cerebrospinal pressure, and
other brain molecular markers (neuron specific enolase, glial
fibrillary acidic protein) [11,12]. Thus, the major advantage of
using S100B is that elevations in serum can be easily measured,
providing a sensitive measure to help rule out major CNS
dysfunction.
An important application of serum S100B testing is the selection
of patients with minor head injury who do not need further
neuroradiological evaluation, as studies comparing CT (comput-
erized tomography) scans and S100B levels have demonstrated
S100B values below 0.1 ng/mL are associated with low risk of
obvious neuroradiological changes (such as intracranial hemor-
rhage) or significant clinical sequelae [10]. In addition, several
papers have shown that the high negative predictive value
(NPV=TN/(TN+FN), where TN= true negative and FN= false
negative) of S100B in several neurological conditions is due to the
fact that serum S100B levels reflect blood-brain barrier perme-
ability changes even in absence of neuronal injury [1–9]. Thus,
serum S100B levels may increase prior to a significant change in
neurological function, or neuronal cell death, which is in
accordance to its function as an astroglial and non-neuronal
protein marker. This is an important clinical finding inasmuch
S100B levels in the normal range rule out cerebrovascular damage
and injury to the CNS in nearly 99% of patients by neurological
imaging [10–13].
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12691Recently, controversy has arisen with regards to the brain
specificity of this protein. Several lines of evidence suggest that
extracerebral sources contribute to S100B serum levels [13]. For
example, in multi-organ system trauma without traumatic head
injury, elevations in serum S100B levels collectively reflect
traumatized fat, muscles, or bones since the blood-brain barrier
remains intact in these situations and therefore, cannot account for
the systemic rise in S100B levels. Similarly, shed blood from
cardiac surgery displayed heightened levels without apparent head
injury [14]. Marathon runners, joggers, basketball players, ice
hockey players, and boxers also have high S100B levels after
engaging in their respective physical activity, which may be the
result of both BBB (blood-brain barrier) opening and muscular
release [15–17].
The objective of this current study was to determine if tissue
sources, outside the brain, contribute significantly to serum levels
of S100B. In this study, we characterized by Western blot the
expression of S100B in human tissue using two different antibodies
and corroborated this data with mass spectrometry. We then
assessed how expression in these tissues affects the current clinical
methods for detection of S100 by using the LIAISONH S100 or
LIAMAT systems (Sangtec-Diasorin), and the Elecsys system
(Roche Diagnostics). Finally, we analyzed 200 subjects to
determine if adiposity or fat S100B affected serum levels.
Methods
Human Subjects
All studies were performed in accordance with the Declaration
of Helsinki and written approval by the IRB Committee at the
Cleveland Clinic. All samples (blood and tissue) were obtained by
written informed consent and given a coded identifier to retain
subject anonymity. Tissue samples were obtained as surplus tissue
from various medical procedures conducted at the Cleveland
Clinic, generously provided by the department of Pathology. For
the purpose of this study we analyzed 200 subjects, consisting of
155 patients and 45 controls (Table 1). Note that our patient
population comprised of individuals with a broad spectrum of
ages, races, and pathologies, which ranges from psychiatric
disorders to brain tumors. We also recruited a large number of
volunteers without any pathology or psychiatric condition, as
detected by a psychiatrist delivering a brief psychiatric exam.
Samples were analyzed by different techniques, the details of
which are presented in the Methods Section and below. We
analyzed tissue protein contents by antibody-dependent assays or
by mass spectrometry (MS). When possible, two antibodies were
used for the detection of different antigen regions in the S100B
protein. BMI (body mass index) was calculated based on the
weight (in kilograms) divided by the square of the patient’s height
(in meters) taken from the medical record.
BBB Disruption
The Cleveland Clinic Brain Tumor Institute provides a
treatment called blood-brain barrier disruption for primary CNS
lymphomas. All procedures were performed after informed
consent was obtained using protocols approved by the Cleveland
Clinic Foundation IRB. In this protocol, intra-arterial mannitol
(1.4 M) is administered via a carotid or vertebral artery, and BBB
disruption was confirmed by contrast CT immediately after
chemotherapy. The details are described elsewhere [18].
Tissue Protein Extraction
Proteins were extracted from various tissues using the Millipore
Total Protein Extraction Kit (Chemicon subsidiary, Temecula,
CA). Briefly, tissues were weighed, chopped into small pieces, and
kept on dry ice. Then 1X TM buffer [13 mL of HEPES (pH 7.9),
MgCl2, KCl, EDTA, sucrose, glycerol, sodium deoxycholate, NP-
40, sodium orthovanadate] and a protease inhibitor cocktail was
added to each tissues at 2.5 mL per gram of tissue and put on ice
for 5 minutes. The tissue was homogenized for 20 seconds and
then put on dry ice for 15 seconds. This cycle was repeated 3
times. The homogenized tissues were rotated at 4uC for 20
minutes and centrifuged at 11,000 rpm at 4uC for 20 minutes. The
supernatant was collected and stored at 280uC until analyzed
further.
Western Blots
Protein concentration was determined by the Bradford assay
method (Bio-Rad, Hercules, CA). Total proteins (50 mg/lane) were
separated on 10–20% polyacrylamide gels with SDS-PAGE at
Table 1. Patient Characteristics.
Grouping N Age
Age
Range
Height
(cm)
Height
Range
(cm)
Weight
(kg)
Weight
Range
(kg)
BMI
(kg/m
2)
BMI
Range
(kg/m
2)
S100B
(ng/mL)
S100B
Range
(ng/mL)
%
Female
Cau-
casian
African
American Other
Ped.
Controls
20 16.6
(1.1)
14–18 171.3
(7.3)
161–
191
67.3
(16.9)
45–118 22.9(5.1) 16.7–38.4 0.11
(0.09)
0.03–
0.42
55.0 14 1 5
Ped.
(Non-Psych)
25 14.3
(3.3)
8–18 156.9
(18.9)
120–
185
65.6
(28.9)
21–111 25.3(7.7) 12.9–38.5 0.23
(0.17)
0.05–
0.70
40.0 19 1 5
Ped.
Psychotic
39 14.3
(2.6)
10–18 162.6
(13.4)
137–
186
68.3
(29.0)
27–205 25.4(9.5) 11.3–76.2 0.26
(0.23)
0.02–
1.11
43.6 18 16 5
Adult
Controls
25 39.1
(11.1)
22–60 169.1
(8.1)
147–
183
68.1
(9.3)
50–82 23.8(2.8) 19.1–31.8 0.08
(0.05)
0.04–
0.27
40.0 13 1 11
Adult
(Non-SVID)
22 62.5
(9.5)
47–80 174.1
(10.1)
155–
189
79.1
(18.4)
54–127 26.1(6.1) 19.3–47.8 0.22
(0.29)
0.01–
0.13
27.3 20 2 0
Adult
(SVID)
59 65.8
(8.0)
49–85 169.6
(10.5)
146–
203
78.8
(16.7)
37–125 27.3(5.1) 15.6–40.7 0.18
(0.15)
0.01–
0.71
40.7 53 6 0
BBBD 10 53.6
(15.8)
21–72 165.3
(7.8)
152–
178
73.8
(23.0)
29–105 26.8(7.4) 10.6–36.0 0.14
(0.04)
0.07–
0.22
80.0 10 0 0
This table describes the patient characteristics of our study patient populations [mean value +/2 (standard deviation)].
doi:10.1371/journal.pone.0012691.t001
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(Millipore Corp., Bedford, MA) by electroblotting at 100 V of
constant voltage for 1 hour. After blocking with TBST and milk
(Tris-buffered saline, 0.05% milk powder, and 0.05% Tween 20)
for at least 2 hours, the membrane was probed overnight at 4uC
either with the Sangtec-Diasorin or OriGene S100B primary
antibody (1:1000). The OriGene monoclonal antibody was made
by immunizing against a synthetic peptide corresponding to
residues on the C-terminus of human S100B. The polyclonal
Sangtec antibody was raised against the whole human protein.
These antibodies were selected because they target different
regions of the S100B protein (see legend of Figure 1). The Sangtec
antibody was also chosen for Western blot analysis because it
constitutes the capture antibody of the LIAISON kit (Figures 2A,
B). After a series of washes, the membrane was incubated with
secondary horseradish peroxidase-conjugated anti-goat IgG anti-
body (rabbit or rat) for 2 hours. Western blots were visualized by
enhanced chemiluminescence reagent (ECL Plus, Amersham
Biosciences, Piscataway, NJ). The dilution for the Sangtec
antibody, which is not commercially available, was derived from
a previous study [14].
Relative Density on Western Blots
Western blots were scanned on a scanner interfaced with a PC
using HP Precision Scan Pro 3.02 analysis software (Hewlett-
Packard Co., Palo Alto, CA). The scanned grayscale images were
saved in an uncompressed TIFF format and further analyzed using
software specifically designed for measuring grayscale image
density, developed by Nonlinear USA, Inc. (Durham, NC)
PhoretixTM ID (Version 2003.01).
Immunoassay Determination
We used colorimetric immunosorbent assay, SangtecH 100
ELISA, by DiaSorin, Inc. (Stillwater, MN) to quantify S100B. The
Figure 1. S100B Antibody Comparison. Twelve different types of human tissues were assessed for S100B expression by two different antibodies
by Western blot. The OriGene monoclonal antibody was made by immunizing against a synthetic peptide corresponding to residues on the C-
terminus of human S100B. The polyclonal Sangtec antibody was raised against the whole human protein. (A) shows the tissue specific expression
level of S100B using the Sangtec-Diasorin antibody and (B) OriGene antibody after Western blot analysis. Regardless of the antibody used, S100B was
found in tissues other than brain. (C) We quantified and compared the results of the two Western blots obtained by the two different antibodies as
well as (D) this data normalized to brain tissue. The rank order of S100B expression is different depending on the antibody used.
doi:10.1371/journal.pone.0012691.g001
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Fujirebio system by Fujirebio Diagnostics, Inc. (Tokyo, Japan) to
measure various mono- and hetero- dimers of S100B. The Elecsys
system (Roche Diagnostics, Indianapolis, IN) was used as well for
the purpose of measuring S100B.
Mass Spectrometry
We used a LC-MS system Finnigan LCQ-Deca ion trap mass
spectrometer system with a Protana microelectrospray ion source
interfaced to a self-packed 10 cm675 um id Phenomenex Jupiter
C18 reversed-phase capillary chromatography column. Data were
analyzed by using all CID spectra collected in the experiment to
search the National Center of Biotechnology Information (NCBI)
non-redundant database with the search program TurboSequest.
All matching spectra were verified by manual interpretation. The
interpretation process was also aided by using the programs
Mascot and Fasta to perform additional searches, as needed.
Statistical Methods
Data are presented as mean 6 standard deviation (SD). JMPH
8.0 (Cary, NC) was used for statistical analysis. Correlation plots
were produced using statistical software by the Origin Lab
Corporation (versions 7.0 and higher, Northampton, MA) to
calculate correlation coefficients (R) and 95% confidence limits.
Significant difference or correlation was assessed by P-values of
,0.05, calculated using the Student’s t-statistic.
Results
We first analyzed S100B protein content in a variety of tissue
samples (Table 2). Western blot analysis revealed that, regardless
of the antibody used, S100B is found in tissues other than brain.
The results in Figure 1A and 1B show protein signals obtained
with the Sangtec or OriGene antibody.
The results presented thus far were obtained with two different
antibodies directed towards the same antigen, yet these results
were not quantitatively consistent. To rule out that the measured
signal may be due to protein other than S100B, we analyzed the
molecular identity of selected lanes shown in Figure 1A and 1B by
MS.
The two antibodies gave comparable but not identical results.
While both revealed a strong signal from brain tissue, muscle and
fat also exhibited strong levels of expression. The data were
quantified to construct the bar graph shown in Figure 1C where
the values are expressed in nanograms per lane. An added
standard of S100B was used to quantify S100B expression in
tissues. In addition, we compared these expression levels to brain
tissue as shown in Figure 1D. Note that when data are normalized
to brain expression, significant levels were seen in extracranial
tissues and the extent of this phenomenon depended on the
antibody used.
Molecular Identity of the S100B Signal
MS analysis confirmed that the brain tissue signal, consistent by
molecular weight with S100B, was indeed this protein (Table 3).
When the same lanes were isolated from fat samples, S100B
expression was similarly found. We chose fat tissue because it was
most consistently reported in the literature to contribute to
Figure 2. Extracranial Detection of S100B. Extracranial sources of S100B revealed on Western blots do not affect the clinical detection of S100B
using the Sangtec-Diasorin immunoassay. (A) The results of two clinically relevant Sangtec-Diasorin immunoassay systems; the fully automated
Liaison (x-axis) was compared with the manual LIA-mat assay kit. There was good correlation between the two systems. (B) A good correlation existed
between two automated (Elecsys by Roche Diagnostics and Liaison by DiaSorin) immunoassays for S100B. (C) The same human tissue protein extracts
used for Western blotting previously were analyzed with the Sangtec-Diasorin immunoassay. In contrast to what we found in Western blots, the brain
is the main chief expressor detected by this method.
doi:10.1371/journal.pone.0012691.g002
Table 2. Surgical Specimen Characteristics.
Tissue Specimen
Primary
Diagnosis Sex Age Race
Bladder Bladder Cancer M 65 Caucasian
Liver Liver Cancer M 57 Caucasian
Kidney RCC M 71 Caucasian
Colon UC M 53 Caucasian
Lung Lung Cancer M 80 Caucasian
Muscle Sarcoma M 67 Black
Pancreas Cyst F 42 Caucasian
Fat Sarcoma F 81 Black
Fat Crohn’s Disease M 50 Caucasian
Brain Epilepsy M 35 Hispanic
Tonsil Hypotrophy F 33 Caucasian
Stomach Unknown M 54 Caucasian
Skin Thigh Mass M 43 Black
Table 2 details the patient characteristics of the surgical specimens used for
Western blotting and ELISA analysis. RCC= Renal Cell Carcinoma, UC=
Ulcerative Colitis.
doi:10.1371/journal.pone.0012691.t002
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analysis also revealed the presence of another protein of the S100
family, namely S100A1 [21].
Results with a Clinically Relevant Platform
Most of the clinical results dealing with the utilization of
S100B as a predictor of neurological disorders were obtained
with one of several immunoassays that are commercially
available (for a complete recent summary see Goncalves et al.,
[13]).
We measured S100B by ELISA (Sangtec-LIAISON; Figure 2C).
With the LIAISON system, brain was the chief expressor, while
other tissues contributed less significantly, if at all to the signal. In
particular, neither muscle nor fat gave a significant signal as it did
in the Western blots. Thus, tissue samples S100B content was
substantially different when using ELISA vs. Western (compare
Figure 2C and Figure 1C).
In addition to this commercially available immunoassay,
previous literature dealing with clinical samples has often used
an automated version of the same test [13]. The results of a direct
comparison between the automated and manual test are shown in
Figure 2A. Note that a good correlation existed between the two
tests. In addition, we compared the results of a clinically relevant
test based on the Sangtec-Diasorin platform with another
commonly employed platform (Roche Diagnostic, Figure 2B).
Again, we noted a good correlation between the two systems.
These results have shown that there is a significant quantitative
difference when comparing results obtained by gel-based analysis
versus ELISA-type immunoassay systems. The latter, produced
comparable results both quantitatively and qualitatively, suggest-
ing that the use of these clinically relevant platforms leads to
meaningful and comparable results.
Molecular Nature of S100B Released by Brain Tissue
The literature dealing with the detection of S100B as an
indicator of neurological dysfunction or BBB leakage was
profoundly affected by the discovery of Marchi, et. al [18] who
demonstrated that upon iatrogenic BBB disruption (BBBD) S100B
levels were elevated minutes after the procedure itself. This
prompted us and others to characterize S100B as an indicator of
BBB damage rather than a protein related to neuronal cell death
or other types of brain injuries [1,2,22–30]. However, recent
findings by others [1,2,13,17,19,22–35] have shed doubt on the
utility of this approach, primarily because of extracranial sources
of S100B. Our data, in fact, show that this is indeed the case and
that tissue other than brain expresses this protein. However, it is
also known that S100B may be detected in its monomeric or
dimeric form. In addition, S100B may form a homo- or hetero-
dimer with its companion S100A1 [21,36].
We therefore wished to investigate the molecular nature of the
S100B extravasating from the human brain under conditions of
iatrogenic BBB disruption (Figure 3). To this end, we utilized
ELISA platforms manufactured by Canag/Fujirebo to specifically
dissect out the signal components due to homo- or hetero-dimers
of S100B and S100A1. In Figure 3, note that BBBD caused an
increase of S100B dimer but not of the S100A1-B heterodimer.
The increase of the B-B homodimer was the principal event that
caused the elevation of the total signal. In other words, these
results demonstrated that the main species of S100B released by
the brain when the blood-brain barrier is disrupted is the S100 B-
B. The numbers above the histogram refer to ng/mL changes
occurred between pre-BBBD and at the time when chemotherapy
was injected. Note that virtually all the increase in total S100B
measured was due to the B-B dimer (0.011 ng/ml). The
quantitative results for total S100 are similar to what published
previously [2].
Do extracranial sources contribute to the clinical test for
serum S100B?
The results we have presented so far unveiled a complex
scenario where several different molecular species act, upon
BBBD, to modify serum values of S100B. We therefore wished to
investigate the S100B values in serum of patients or controls
across, to our knowledge, the broadest published population of
subjects. The results are summarized in Figure 4 and Table 1.
Given the expression of S100B in adipocytes, we investigated the
relationship between fat content and S100B levels. This was
achieved by determining body mass index (BMI; see Methods for
calculations). Note that when serum samples from 200 subjects
were analyzed, no correlation was found between BMI (or body
weight in kg, not shown) and S100B levels (Figure 4). This suggests
that while unquestionably S100B is present in fat, it does not alter
the S100B serum concentration in ‘‘normal’’ volunteers, patients
affected by a variety of disorders, or pediatric controls or children
with various illnesses. These results are also consistent with
findings by Biberthaler et al. [27,37–40] who evaluated the
relevance of BMI in serum values of S100B in a large number of
controls and traumatic brain injury patients.
Discussion
The main contribution of this article to our understanding of
S100B use in the clinical setting is that in spite of robust expression
by extracranial sources, changes in serum levels are primarily
dictated by extravasation across the disrupted BBB. In addition,
we have shown that the main molecular species of total S100B
related to blood-brain barrier disruption is the S100B homodimer.
Table 3. Mass Spectrometry Characterization of Protein Bands.
Tissue Type Proteins Detected Nomenclature
Human Brain S100B, S100A S100 calcium binding protein A1 (Acc# 5454032,11 kDa)
S100 protein, beta polypeptide (Acc# 5454034, 11 kDa)
Human Fat (F) S100B, S100A S100 calcium binding protein A1 (Acc# 5454032, 11 kDa)
S100 protein, beta polypeptide (Acc# 5454034, 11 kDa)
Human Fat (M) S100B, S100A S100 calcium binding protein A1 (Acc# 5454032, 11 kDa)
S100 protein, beta polypeptide (Acc# 5454034, 11 kDa)
Mass spectrometry analysis revealed that human brain and fat tissue contained S100B as well as the presence of another protein of the S100 family, namely S100A.
doi:10.1371/journal.pone.0012691.t003
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To our knowledge, this is the most exhaustive study ever
performed to compare and cross-validate various approaches to
the detection of S100B. In addition, we have used a vast array of
subjects and tissues. Western blot analysis revealed that,
regardless of the antibody used, S100B is found in tissues other
than brain. Our results show, surprisingly, a poor correlation
between different antibodies. While cross-reactivity of antibodies
is well known and widely accepted, we were nevertheless
surprised that the rank order of expression depended on the
antibodies used. In addition, testing by ELISA showed a different
profile, where expression by extracranial sources was less
prominent. We were, however, able to show that the gel-based
approach was sensitive for S100B which was detected by MS.
The co-expression of S100A1 was expected, based on results by
others [41]. Although discussion of the possibilities of why we
observed such varying expressions of S100B protein between the
platforms of Western blot and ELISA is a very noteworthy,
adequate analysis is beyond the scope of this paper. These
findings may have implications beyond recent S100B research
efforts, inasmuch as most of our current knowledge on protein
function is based on antibody detection of levels by gel
electrophoresis. The use of antibody-independent detection
therefore appears advisable.
Limitations and strengths for basic scientists
As stated above, our results are not comforting for the basic
scientist. Western blotting is an easy and reproducible technique
that enjoys wide popularity. Our concerns are not unique [42]. We
found different levels of S100B expression by using two different
antibodies and found poor qualitative and quantitative correlation.
Similar results were obtained in rodent tissue with other
commercially available antibodies (data not shown). Such discrep-
ancies may pose a significant problem, as they substantially
impinge on and alter the conclusions drawn from experiments
including those aiming at discoveries of disease treatment
modalities or with diagnostic purpose.
Another practical limitation of this study, due to the diversity
and number of patients included, was the use of the BMI
calculation to assess individuals’ relative body fat. Recent studies
on nutrition and metabolism have validated techniques such as
ultrasound, air displacement plethysmography and bioelectrical
impedance to be superior to BMI for accurately measuring body
fat [43]. These techniques were not readily available nor could we
easily implement them and therefore utilized the BMI calculation
not only out of practicality, but also out of the widespread use of it
in other S100B studies.
Based on these observations, it may be desirable to incorporate
any or all of the following to ascertain that an observed signal is
Figure 3. BBB Opening: Comparison of Various Forms of S100B. The main species of S100B released from BBB disruption is the B-B dimer as
measured using the CanAg/Fujirebio ELISA system. The rise in total S100B after BBB opening was 0.011 ng/ml, which was found to be accounted for
by the concomitant rise of the B-B dimer. There was virtually no change in the concentration of the A1-B dimer with BBB opening. We determined the
concentration of the A1-B dimer by using the CanAg S100A1B EIA solid-phase, two-step, non-competitive immunoassay based on two mouse
monoclonal antibodies specific for two different epitopes specifically expressed in S100A1B. The assay thus determines S100A1B with very low cross-
reactivity with S100BB or other forms of S100. Similarly, to measure the B-B dimer we used the CanAg S100BB EIA solid-phase, one-step, non-
competitive immunoassay based on two mouse monoclonal antibodies specific for two different epitopes specifically expressed in S100BB. This assay
thus determines S100BB with very low cross-reactivity with S100A1B or other forms of S100.
doi:10.1371/journal.pone.0012691.g003
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by increased mRNA. Therefore, if release of S100B is due to a
pathology initiating active synthesis rather than by passive release
from necrotic astroglial cells (as in stroke) quantitative RT-PCR of
S100B messenger RNA would be appropriate to further support
any observations; 2) Antibody-independent methods such as MS
should be included for validation of target recognition; 3) When
possible HPLC (high-performance liquid chromatography) should
be used in parallel or serial experiments.
Clinical significance
While the results we present may be disappointing for the bench
researcher, we also demonstrated that the clinical detection of
S100B is more reproducible and robust. In addition, the type of
instrument, or the platform used did not alter the results, nor did it
affect the predictive value of the test. The clinical tests all measure
total S100B, regardless of it monomeric or dimeric state, nor do
they consider whether S100B is bound to S100B or S100A1.
Preliminary results with tests detecting only S100B-S100B dimers
have demonstrated, as expected, that the ceiling for ‘‘normal
values’’ is significantly lower than the published ‘‘0.1 ng/ml’’
dogma [1,6,10,14,19,24,40,44–46].
We confirm that S100B was not exclusively produced by CNS
cells. We found that muscle and fat were chief extracranial
expressors, which is consistent with the literature [19]. However,
our results are in sharp contrast with the findings linking serum
S100B to BMI [20]. These results used the same system used by us
(LIAMAT), but their sample size was significantly smaller. In
addition, no cross-validation with other detection systems was
used. Our range of BMI values was larger, the ages broader, and
the racial samples were balanced to reflect the general US
population. We also included diseased patients’ samples, to add to
the clinical significance of the findings. We found no correlation
between S100B and weight or height, but found, as expected, a
correlation with age [47]. When the values were restricted within a
given category (e.g., pediatric controls in Table 1), we still found no
correlation between BMI and S100B. Why these results are in
sharp contrast with Steiner et al. [20] remains at present unknown.
Our results show that extracranial sources of S100B do not
significantly affect serum levels. Thus, the reported low sensitivity
and positive predictive value (relative to the reported strong
specificity and negative predictive value) for S100B [24] is not
apparently due to extracranial release of the protein. Further
studies are needed to explore the use of S100B dimers as tools in
neurodiagnostics.
There are two possible explanations that may account for the
discrepancy between previous studies documenting elevated
S100B levels from extracranial sources and our present findings.
There have been recent reports that serum S100B levels are
positively correlated with body mass index without evidence of
traumatic brain injuries. Interestingly, obesity has been hypoth-
esized to be a state of heightened systemic oxidative stress and
inflammatory response, which is mechanistically linked to other
co-morbid conditions such as hypertension and small vessel
disease. Therefore, it is not clear whether obesity itself or
obesity-associated comorbidities contribute to a rise in serum
S100B in the previous studies. In our study, we directly measured
the tissue specific expression of S100B in addition to serum S100B,
which represents a collective source from multiple disease
processes. Our study showed that an increase in fat mass might
not in isolation be a major contributor to elevated S100B levels.
Rather, obesity-related diseases are likely contributors. For
example, small vessel ischemic disease associated with obesity is
a source of serum S100B [24,48].
Figure 4. Correlation Between BMI and S100B. Given the expression of S100B in adipocytes, we investigated the relationship between fat
content and S100B levels using 200 subjects. No correlation was found between BMI and S100B levels.
doi:10.1371/journal.pone.0012691.g004
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in higher serum levels of S100B. However, Fazio et al.
demonstrated that S100B antibodies from certain ELISA kits
might cross-react with other proteins found in serum[14]. It is
difficult to characterize biomarkers in serum because of the wide
range of protein concentrations and predominance of 10 to 20
proteins (albumin, immunoglobulins, etc.) that overwhelm the less
abundant signals. This may suggest that in other studies yet
unknown cross-reactants were artificially increasing the apparent
S100B levels measured in serum.
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